India's Elder calls on Deloitte; A*Star investigators link protein with memory, learning;

@FierceBiotech: Cash-flush Versartis swings for an $80M IPO to advance its orphan drug. News | Follow @FierceBiotech

@JohnCFierce: AstraZeneca dispatches an advance science team to future HQ campus. Story | Follow @JohnCFierce

@DamianFierce: Lilly moves on from a breast cancer setback as ramucirumab aces Phase III in lung cancer. More | Follow @DamianFierce

@EmilyMFierce: Acid-bath stem-cell study under investigation. Story via Nature | Follow @EmilyMFierce

> India's Elder Pharmaceuticals has brought in Deloitte to help reposition the company and launch new products. Story

> Scientists at A*Star say they have defined a link between the protein SNX27 and the pathway regardiong memory and learning, which could be important for Down syndrome research. Release

Medical Device News

@FierceMedDev: Our latest issue of FierceDiagnostics is ready for you. Highlights: news on a new depression biomarker and HIV tests. Report | Follow @FierceMedDev

@MarkHFierce: The rapidly escalating fortunes of a Chinese med device company created another billionaire there. Article | Follow @MarkHFierce

@MichaelGFierce: UCLA-developed contact lens uses a nanodiamond gel to deliver glaucoma drugs. More from FierceDrugDelivery | Follow @MichaelGFierce

@EmilyWFierce: ICYMI: Welsh government refuses to cover costs associated with faulty PIP breast implants. Item | Follow @EmilyWFierce

> Medtronic goes super tiny with its new wireless insertable cardiac monitoring device. Story

> Stryker's first M&A target of 2014: A German surgical equipment maker. More

> Medical device tax jobs toll: 33K and counting, says AdvaMed. Article

> J&J gets good news in vaginal mesh suit. News

Pharma News

@FiercePharma: Icahn is touting the Actavis-Forest deal as "another victory for activism." Release | Follow @FiercePharma

@EricPFierce: FDA picks 13 firms to participate in a pilot program that gives them expedited entry of 5 drugs to the U.S. Release | Follow @EricPFierce

@CarlyHFierce: From FiercePharmaMarketing: Eisai's revved-up Belviq marketing starting to pay off, analysts say. Story | Follow @CarlyHFierce

> Novo Nordisk targets Mexico for early obesity drug launch. Article

> Prosecutors step up Diovan ad probe in raid on Novartis' Tokyo offices. Piece

Drug Delivery News

> UCLA-developed contact lens uses a nanodiamond gel to deliver glaucoma drugs. Article

> Targeted gold nanoshells radiate heat to improve cancer drug effect. Story

> 3M to develop inhaled airway inflammation treatments with Delaware's Invion. News

> Stem cell scaffold takes delivery issues out of tissue regeneration. Article

> 'Sticky' nanoparticles could help keep arteries open without a stent. Article

> With rejection, FDA says Durect's pain treatment Posidur needs further safety studies. Brief

Diagnostics News

> Cambridge U. researchers have discovered a biomarker for depression risk in boys. Article

> Sedia Biosciences wins NIH funding to develop an FDA-regulated HIV test. News

> Decision Diagnostics raised $12.7M for J&J glucose test strip patent countersuits. Story

> Ariosa's prenatal test gains crucial New York lab licensing certification. News

> Chembio teams with Malaysian outfit to bring its rapid HIV/syphilis tests into Asia. Story

> French operation raises nearly $56.4M to advance molecular imaging tools. Brief

Pharma Marketing News

> Novartis advertising probe intensifies with Tokyo office raid. News

> Simplify, simplify? FDA to study pared-down side effects in TV ads. Story

> Forest to discontinue old Namenda to 'force switch' patients to XR version. Article

> Sunshine Act data is now due, but some provisions remain murky. Story

> To win over patients, pharma needs to tell the truth, and nothing but, expert says. Analysis

> Chelsea scored FDA approval for Northera, but the launch is no sure bet. Item

Suggested Articles

A TGen-led research team found that increased activity of the gene AEBP1 drives severe liver fibrosis in nonalcoholic steatohepatitis.

Days after announcing its R&D chief was stepping down, Gilead announced it will be buying a few of Novartis’ unwanted early-stage infection assets.

Mallinckrodt is teaming up with Silence Therapeutics to develop an RNAi program aimed at a group of proteins that play a part in promoting inflammation.